Showing results (1-10 of 262) with videos related to
Sort By:
Pageof 27
Cancer Treatment Reviews|July 22, 2019
Opportunities of circulating tumor DNA in lung cancerTing-Hui Wu, Emily Han-Chung Hsiue, James Chih-Hsin YangExpert Review of Respiratory Medicine|December 9, 2016
New data on clinical decisions in NSCLC patients with uncommon EGFR mutationsTing-Hui Wu, Emily Han-Chung Hsiue, Jih-Hsiang Lee, et al.Future Oncology (London, England)|February 16, 2023
Afatinib for the treatment of non-small-cell lung cancer with unusual EGFR mutations: a plain language summaryJames Chih-Hsin YangJournal of the Formosan Medical Association = Taiwan Yi Zhi|May 1, 2018
Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese studyTing-Hui Wu, Lukas Jyuhn-Hsiarn Lee, Chang-Tsu Yuan, et al.Drugs|December 24, 2010
Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutationsChia-Chi Lin, James Chih-Hsin YangCancer Cell|February 13, 2024
Re-inventing a better wheel? Serplulimab for squamous cell lung cancerDerek De-Rui Huang, James Chih-Hsin YangAnticancer Research|March 31, 2021
CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung CancerSebastian Griesing, Bin-Chi Liao, James Chih-Hsin YangTherapeutic Advances in Medical Oncology|December 6, 2019
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patientsBin-Chi Liao, Sebastian Griesing, James Chih-Hsin YangAnnual Review of Medicine|January 28, 2020
Precision Management of Advanced Non-Small Cell Lung CancerChing-Yao Yang, James Chih-Hsin Yang, Pan-Chyr YangClinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2011
Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLCRené H Medema, Chia-Chi Lin, James Chih-Hsin YangPageof 27